Image

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 8,050.00 USD Million
Diagram Market Size (Forecast Year) USD 19,230.00 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market, By Drugs Type (Talazoparib, Veliparib, Olaparib, Others), Indication Type (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2030.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Analysis and Size

Global Poly (ADP-ribose) polymerase inhibitors, which are often called PARP inhibitors, are targeted therapies that are used to treat cancer. PARP is a protein that has a role in cellular growth, regulation and cell repair which helps the cancer cells repair themselves and survive. The PARP inhibitor stops the cancer cells being repaired which causes the cells to die and so reduces tumor growth. In cancers where the tumour suppressor gene is faulty the cancer cells are repaired only by PARP. The PARP repair is incomplete which means the cancer cells DNA is repaired to a point where it just has a small amount of damage and the cancer cells are able to able to grow and divide.

Data Bridge Market Research analyses that the global poly (ADP-Ribose) polymerase (PARP) inhibitors market, which was USD 8,050.00 million in 2022, would rocket up to USD 19,230.00 million by 2030, and is expected to undergo a CAGR of 11.5% during the forecast period. “Hospitals” dominates the end users segment of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market owing to the wide range of applications found in hospitals. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Drugs Type (Talazoparib, Veliparib, Olaparib, Others), Indication Type (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)

Countries Covered

U.S., Canada, and Mexico in North America, Germany, France, the U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of the Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Pfizer Inc. (U.S.), CLOVIS ONCOLOGY (U.S.), AstraZeneca (U.S.), Merck & Co. Inc.  (U.S.), Myriad Genetics, Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Johnson & Johnson Services, Inc.  (U.S.), AbbVie Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel)among others

Market Opportunities

  • Rising number of research activities
  • Ongoing clinical trials

Market Definition

Poly (ADP-ribose) polymerase inhibitors are a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfer them to the target proteins. This supports restoring DNA when it is damaged. Many factors, including exposure to UV rays, radiation, some anti-cancer drugs, or other substances in the environment, can damage DNA. PARP inhibitors block an enzyme critical to the repair of single-stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways. The major factor attributable to the market growth includes the growing prevalence of cancer all over the globe. For instance, ovarian cancer is the second most common gynecologic cancer in the U.S.

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Dynamics

Drivers

  • Growing Adoption in Advanced First line Settings to Accelerate PARP indicator Sales

The leading factor favoring the growth in the market is the growing burden of prostate cancer worldwide. According to the World Cancer Research Fund, prostate cancer is the 2nd most common type of cancer found in men and 4th most commonly occurring cancer overall. In addition, increasing adoption of olaparib in advanced first-line settings for prostate cancer treatment is expected to spur the sales of PARP indicators in the segment.

As PARP inhibitors are increasingly being used with other breast cancer treatments, such as radiation and chemotherapies, for repairing DNA damage post-exposure to ultraviolet (UV) radiation, the rising prevalence of breast cancer is expected to favor the growth in the market.

  • Rising number of geriatric population

Expanding geriatric population worldwide is predicted to favor the Poly (ADP-Ribose) Polymerase (PARP) inhibitors demand as this population is more prone to develop diseases. The number of persons above 65 years is projected to double in the coming years. Old-age people are prone to various chronic diseases such as chronic disorders, which can foster the demand for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors across the globe.

The increasing geriatric population, higher volume for digital imaging, and overpowering medical needs demand the rise in poly (ADP-Ribose) polymerase (PARP) inhibitors market growth. Affordability for advanced technologies with poly (ADP-RIBOSE) polymerase (PARP) inhibitors aided units have seen a rise over the past few years. Manufacturers of poly (ADP-RIBOSE) polymerase (PARP) inhibitors help in enhancing the therapeutic and healthcare application.

  • Rise in inclination towards Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

Chronic diseases can range from mild to severe and cause serious issues if left untreated. The major factors for the growth of the global Poly (ADP-ribose) polymerase inhibitors market are the increasing awareness of the importance of health, the aging population, and the development of new products and technologies. Recently, higher emphasis has been placed on health expertise, which will further act as a driver that will lead to the growth of the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market in the above-mentioned projected timeframe.

Moreover, rise in inclination towards Poly (ADP-Ribose) Polymerase (PARP) Inhibitors because of the various benefits offered by it, such as lower doses to patients in most cases, reasonable alternatives in terms of cost and improved resolution, shorter acquisition times for the resolution needed and detailed results accelerate the poly (ADP-Ribose) polymerase (PARP) inhibitors market growth.

Opportunity

  • Rising innovations in the industry

Furthermore, rising innovations in the industry are pointing towards the linkage between chronic disease and medical conditions such as diabetes, heart disease, rheumatoid arthritis, and certain types of cancer. Health experts and medical professionals are increasingly collaborating in order to provide optimal care, especially in the cases of medically compromised patients owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, it is observed that emerging technologies are increasingly adopted through drugs. By embracing these improvements, the healthcare industry is increasingly becoming more patient-centric and fostering greater patient trust. Furthermore, growing convenience and consistency. This will further expand the market's growth rate in the future.

Restraints/Challenges

  • High cost associated with treatment and diagnostic methods

On the other hand, high cost associated with treatment and diagnostic methods and unfavorable reimbursement scenario are expected to obstruct the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market growth. Moreover, limited operating revenue opportunities for research and development of targeted therapies by various pharmaceutical industries is projected to challenge the poly (ADP-Ribose) polymerase (PARP) inhibitors market in the forecast period mentioned above.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In May 2019, Clovis Oncology, Inc., American pharmaceutical company, announced entering in a collaboration with two companies - Foundation Medicine Inc. and Bristol-Myers Squibb Company for initiating Phase II studies to evaluate nivolumab combination with rucaparib in patients with endometrial ovarian cancer

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market  Scope

The market is segmented on the basis of type, treatment type, drugs, indication type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs Type

  • Talazoparib
  • Veliparib
  • Olaparib
  • Others

Indication Type

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market   Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drug type, indicator type, end user and distribution channelas referenced above.

The countries covered in the market  report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of the Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.   

North America is expected to dominate the global poly (ADP-Ribose) polymerase (PARP) inhibitors market due to the presence of major key players, growing initiatives by the local government for the improvement of health care, and provision of skilled staff to address the high unmet needs in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to the increasing geriatric population and growing awareness amongst consumers about overall health.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global poly (ADP-Ribose) polymerase (PARP) inhibitors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kinds of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2015-2021.

Competitive Landscape and Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market are:

  • Pfizer Inc. (U.S.)
  • CLOVIS ONCOLOGY (U.S.)
  • AstraZeneca (U.S.)
  • Merck & Co. Inc.  (U.S.)
  • Myriad Genetics, Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K.)
  • Johnson & Johnson Services, Inc.  (U.S.)
  • AbbVie Inc. (U.S.)
  • Myriad Genetics Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel) 


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market will be worth USD 19,230.00 million by 2030.
The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Rate is 11.5% during the forecast period.
The Growing Adoption in Advanced First line Settings to Accelerate PARP indicator Sales, the Rising geriatric population, and the Rise in inclination towards Poly (ADP-Ribose) Polymerase (PARP) Inhibitors are the Growth Drivers of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market.
The type, treatment type, drugs, indication type, end user, and distribution channel. are the factors on which the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market research is based.
The Clovis Oncology, Inc., American pharmaceutical company, announced entering in a collaboration with two companies - Foundation Medicine Inc. and Bristol-Myers Squibb Company for initiating Phase II studies to evaluate nivolumab combination with rucaparib in patients with endometrial ovarian cancer are the latest developments in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials